<DOC>
	<DOCNO>NCT02640612</DOCNO>
	<brief_summary>The main objective trial provide long-term safety , PK , immunogenicity data BI 695501 administer via prefilled syringe patient Rheumatoid Arthritis complete Trial 1297.2 . The primary endpoint thereby number ( proportion ) patient drug-related AEs treatment phase . The secondary objective trial assessment Long-term efficacy BI 695501 evaluation : - change Baseline DAS28 ( ESR ) Week 48 - proportion patient meet ACR20 response criterion Week 48 - proportion patient meet ACR/European League Against Rheumatism ( EULAR ) definition remission Week 48 - proportion patient EULAR response ( good response , moderate response , response ) Week 48 .</brief_summary>
	<brief_title>Long-term Assessment Safety Efficacy BI 695501 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : All patient must sign date Informed Consent Form consistent ICH GCP guideline local legislation prior participation trial ( i.e. , prior trial procedure , include medication washout restriction ) willing follow protocol . Adult patient moderately severely active RA complete Trial 1297.2 , wish participate extension trial investigator´s assessment benefit receive BI 695501 . Patients willing able selfadminister BI 695501 prefilled syringe . Willing use reliable mean contraception throughout trial participation ( female ) willing use acceptable method contraception 6 month follow completion discontinuation trial medication male female ) . Exclusion criterion : Investigatorreported drugrelated SAEs Trial 1297.2 ACR functional Class IV wheelchair/bed bound Primary secondary immunodeficiency ( history , currently active ) Positive QuantiFERON test Known clinically significant coronary artery disease significant cardiac arrhythmia severe congestive heart failure ( NYHA Classes III / IV ) , interstitial lung disease Anaphylactic reaction hypersensitivity adalimumab Trial 1297.2 History / recent evidence cancer incl . solid tumour , hematologic malignancy , carcinoma situ ( certain exception permit ) Positive serology HBV HCV Planned live virus bacterial vaccination trial , 3 month last dose trial drug Receipt treatment ( include biologic therapy ) may place patient unacceptable risk trial Significant disease ( disease may ( ) put patient risk participation ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial ) RA and/or significant uncontrolled disease Women : premenopausal ( last menstruation 1 year prior screen ) , sexually active , pregnant nursing , childbearing potential practicing acceptable method birth control , plan use acceptable method birth control throughout trial Current inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , etc . ) systemic autoimmune disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , pulmonary fibrosis , etc. ) . Secondary Sjögren´s syndrome secondary limit cutaneous vasculitis RA permit Any plan surgical procedure , include bone/joint surgery/synovectomy duration trial Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment iv . antiinfectives within 4 week Screening Visit completion oral antiinfectives within 2 week Screening Visit Serious infection opportunistic infection 1297.2 trial Any acquire neurological , vascular , systemic demyelinate disorder might affect efficacy assessment , particular , joint pain swelling ( e.g. , Parkinson´s disease , cerebral palsy , diabetic neuropathy ) occur 1297.2 trial . Currently active alcohol drug abuse Treatment iv . Gamma Globulin Prosorba® Column 1297.2 trial Planned treatment iv . intramuscular , intraarticular parenteral corticosteroid AST ALT &gt; 1.5 time upper limit normal ( ULN ) Hemoglobin &lt; 8.0 g/dL Platelets &lt; 100,000/µL Leukocyte count &lt; 4000/µL Creatine clearance &lt; 60 mL/min Current participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>